Design of curcumin loaded cellulose nanoparticles for prostate cancer

Murali Yallapu, Mitch Ray Dobberpuhl, Diane Michele Maher, Meena Jaggi, Subhash Chauhan

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Prostate cancer (PC) is the most frequently diagnosed disease in men in the United States. Curcumin (CUR), a natural diphenol, has shown potent anti-cancer efficacy in various types of cancers. However, suboptimal pharmacokinetics and poor bioavailability limit its effective use in cancer therapeutics. Several successful CUR nanoformulations have recently been reported which improve upon these features; however, there is no personalized safe nanoformulation for prostate cancer. This study contributes two important scientific aspects of prostate cancer therapeutics. The first objective was to investigate the comparative cellular uptake and cytotoxicity evaluation of β-cyclodextrin (CD), hydroxypropyl methylcellulose (cellulose), poly(lactic-co-glycolic acid) (PLGA), magnetic nanoparticles (MNP), and dendrimer based CUR nanoformulations in prostate cancer cells. Curcumin loaded cellulose nanoparticles (cellulose-CUR) formulation exhibited the highest cellular uptake and caused maximum ultrastructural changes related to apoptosis (presence of vacuoles) in prostate cancer cells. Secondly, the anti-cancer potential of the cellulose-CUR formulation was evaluated in cell culture models using cell proliferation, colony formation and apoptosis (7-AAD staining) assays. In these assays, the cellulose-CUR formulation showed improved anti-cancer efficacy compared to free curcumin. Our study shows, for the first time, the feasibility of cellulose-CUR formulation and its potential use in prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)120-128
Number of pages9
JournalCurrent Drug Metabolism
Volume13
Issue number1
StatePublished - Jan 1 2012

Fingerprint

Curcumin
Cellulose
Nanoparticles
Prostatic Neoplasms
Neoplasms
Assays
Cells
Apoptosis
Dendrimers
Pharmacokinetics
Cyclodextrins
Cell proliferation
Cytotoxicity
Vacuoles
Cell culture
Biological Availability
Therapeutics
Cell Culture Techniques
Cell Proliferation
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Biochemistry

Cite this

Design of curcumin loaded cellulose nanoparticles for prostate cancer. / Yallapu, Murali; Dobberpuhl, Mitch Ray; Maher, Diane Michele; Jaggi, Meena; Chauhan, Subhash.

In: Current Drug Metabolism, Vol. 13, No. 1, 01.01.2012, p. 120-128.

Research output: Contribution to journalArticle

Yallapu, Murali ; Dobberpuhl, Mitch Ray ; Maher, Diane Michele ; Jaggi, Meena ; Chauhan, Subhash. / Design of curcumin loaded cellulose nanoparticles for prostate cancer. In: Current Drug Metabolism. 2012 ; Vol. 13, No. 1. pp. 120-128.
@article{9534cda08357447b97a3a907904bc834,
title = "Design of curcumin loaded cellulose nanoparticles for prostate cancer",
abstract = "Prostate cancer (PC) is the most frequently diagnosed disease in men in the United States. Curcumin (CUR), a natural diphenol, has shown potent anti-cancer efficacy in various types of cancers. However, suboptimal pharmacokinetics and poor bioavailability limit its effective use in cancer therapeutics. Several successful CUR nanoformulations have recently been reported which improve upon these features; however, there is no personalized safe nanoformulation for prostate cancer. This study contributes two important scientific aspects of prostate cancer therapeutics. The first objective was to investigate the comparative cellular uptake and cytotoxicity evaluation of β-cyclodextrin (CD), hydroxypropyl methylcellulose (cellulose), poly(lactic-co-glycolic acid) (PLGA), magnetic nanoparticles (MNP), and dendrimer based CUR nanoformulations in prostate cancer cells. Curcumin loaded cellulose nanoparticles (cellulose-CUR) formulation exhibited the highest cellular uptake and caused maximum ultrastructural changes related to apoptosis (presence of vacuoles) in prostate cancer cells. Secondly, the anti-cancer potential of the cellulose-CUR formulation was evaluated in cell culture models using cell proliferation, colony formation and apoptosis (7-AAD staining) assays. In these assays, the cellulose-CUR formulation showed improved anti-cancer efficacy compared to free curcumin. Our study shows, for the first time, the feasibility of cellulose-CUR formulation and its potential use in prostate cancer therapy.",
author = "Murali Yallapu and Dobberpuhl, {Mitch Ray} and Maher, {Diane Michele} and Meena Jaggi and Subhash Chauhan",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "120--128",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Design of curcumin loaded cellulose nanoparticles for prostate cancer

AU - Yallapu, Murali

AU - Dobberpuhl, Mitch Ray

AU - Maher, Diane Michele

AU - Jaggi, Meena

AU - Chauhan, Subhash

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Prostate cancer (PC) is the most frequently diagnosed disease in men in the United States. Curcumin (CUR), a natural diphenol, has shown potent anti-cancer efficacy in various types of cancers. However, suboptimal pharmacokinetics and poor bioavailability limit its effective use in cancer therapeutics. Several successful CUR nanoformulations have recently been reported which improve upon these features; however, there is no personalized safe nanoformulation for prostate cancer. This study contributes two important scientific aspects of prostate cancer therapeutics. The first objective was to investigate the comparative cellular uptake and cytotoxicity evaluation of β-cyclodextrin (CD), hydroxypropyl methylcellulose (cellulose), poly(lactic-co-glycolic acid) (PLGA), magnetic nanoparticles (MNP), and dendrimer based CUR nanoformulations in prostate cancer cells. Curcumin loaded cellulose nanoparticles (cellulose-CUR) formulation exhibited the highest cellular uptake and caused maximum ultrastructural changes related to apoptosis (presence of vacuoles) in prostate cancer cells. Secondly, the anti-cancer potential of the cellulose-CUR formulation was evaluated in cell culture models using cell proliferation, colony formation and apoptosis (7-AAD staining) assays. In these assays, the cellulose-CUR formulation showed improved anti-cancer efficacy compared to free curcumin. Our study shows, for the first time, the feasibility of cellulose-CUR formulation and its potential use in prostate cancer therapy.

AB - Prostate cancer (PC) is the most frequently diagnosed disease in men in the United States. Curcumin (CUR), a natural diphenol, has shown potent anti-cancer efficacy in various types of cancers. However, suboptimal pharmacokinetics and poor bioavailability limit its effective use in cancer therapeutics. Several successful CUR nanoformulations have recently been reported which improve upon these features; however, there is no personalized safe nanoformulation for prostate cancer. This study contributes two important scientific aspects of prostate cancer therapeutics. The first objective was to investigate the comparative cellular uptake and cytotoxicity evaluation of β-cyclodextrin (CD), hydroxypropyl methylcellulose (cellulose), poly(lactic-co-glycolic acid) (PLGA), magnetic nanoparticles (MNP), and dendrimer based CUR nanoformulations in prostate cancer cells. Curcumin loaded cellulose nanoparticles (cellulose-CUR) formulation exhibited the highest cellular uptake and caused maximum ultrastructural changes related to apoptosis (presence of vacuoles) in prostate cancer cells. Secondly, the anti-cancer potential of the cellulose-CUR formulation was evaluated in cell culture models using cell proliferation, colony formation and apoptosis (7-AAD staining) assays. In these assays, the cellulose-CUR formulation showed improved anti-cancer efficacy compared to free curcumin. Our study shows, for the first time, the feasibility of cellulose-CUR formulation and its potential use in prostate cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84857583365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857583365&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 120

EP - 128

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 1

ER -